Summary
Forty-nine patients with metastatic or recurrent renal cell carcinoma were treated on a phase II trial of Echinomycin. Treatment consisted of Echinomycin 1.25 mg/m2 intravenously every 28 days. Among the 47 evaluable patients there were no complete responses and only one partial response for an overall response rate of 2% (95% confidence interval, 0–11%). Eighteen patients (38%) experienced toxicity of grade 3 or worse. The most common toxicities were nausea and vomiting. The results of this study indicate that Echinomycin is not sufficiently active to warrant further trials for the treatment of renal cell carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Waring MJ, Wakelin LPG: Echinomycin: a bifunctional intercalating antibiotic. Nature 252: 653–657, 1974
Hale EF, Candliffe E, Reynolds PE, Richmond MH, Waring MJ (eds.).The molecular basis of antibiotic action. London: Wiley Publishing Company, 1972: 173–277
Echinomycin (NSC 526417) Clinical Brochure. Division of Cancer Treatment, NCI, Bethesda, Maryland, August 1982
Pazdur R. Haas CD, Baker LH, Leichman CG, Decker D: Phase I study of echinomycin. Cancer Treat Rep 71: 1217–1219 1987
Harvey JH, McFadden M, Andrews WG, Byrne PJ, Ahlgren JD, Wooley PV: Phase I study of echinomycin adminsitered on an intermittent bolus schedule. Cancer Treat Rep 69:1365–1368, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marshall, M.E., Wolf, M.K., Crawford, E.D. et al. Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma. Invest New Drugs 11, 207–209 (1993). https://doi.org/10.1007/BF00874157
Issue Date:
DOI: https://doi.org/10.1007/BF00874157